Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?
Cancer, 06/04/09
Bria E et al. - In a trial to quantify the magnitude of benefit of the addition of hormone treatment (HT) to exclusive radiotherapy for locally advanced prostate cancer (PCa), it was found that hormone suppression plus radiotherapy significantly decreases recurrence and mortality of pts with localized PCa, without affecting toxicity.
Methods- Event-based relative risks (RR) with 95% confidence intervals (CIs) were derived through a random-effect model.
- Differences in primary (biochemical failure and clinical progression-free survival) and secondary outcomes (cancer-specific survival, overall survival [OS], recurrence patterns, and toxicity) were explored.
- Absolute differences and numbers of pts needed to treat (NNT) were calculated.
- A heterogeneity test, a metaregression analysis with clinical predictors of outcome, and a correlation analysis for surrogate endpoints were also performed.
- 7 trials (4387 pts) were gathered.
- Hormone suppression significantly decreased both biochemical failure and clinical progression-free survival, with absolute differences of 10% and 7.7%, respectively, which translates into 10 and 13 NNT.
- Cancer-specific survival and OS were also significantly improved by the addition of HT, without significant heterogeneity, with absolute differences of 5.5% and 4.9%, respectively, which translates into 18 and 20 NNT.
- Local and distant relapse were significantly decreased by HT, by 36% and 28%, respectively, and no significant differences in toxicity were found.
- Primary and secondary efficacy outcomes were significantly correlated.
Related Articles
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Relevance Score: 72%
Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection
The Journal of Urology, 11/13/09
Relevance Score: 71%
A prospective study of lifetime physical activity and prostate cancer incidence and mortality
British Journal of Cancer, 11/02/09
Relevance Score: 71%
Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men
The Prostate, 11/02/09
Relevance Score: 71%
Prostate specific antigen for early detection of prostate cancer: longitudinal study
British Medical Journal, 10/08/09
Relevance Score: 71%
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Expression of Prostate Apoptosis Response (Par-4) Is Associated with Progesterone Receptor in Breast Cancer
Archives of Medical Research, 12/20/09
DNA Copy Number Changes in Gastric Adenocarcinomas: High Resolution–Comparative Genomic Hybridization Study in Turkey
Archives of Medical Research, 12/20/09
Evaluation of an alternative model of anticoagulant care
Irish Journal of Medical Science, 12/20/09
Today in Nephrology/Urology...keeping you current
Receive free subspecialty "5-minute updates" via email
Biological variation of cystatin C and creatinine
Scandinavian Journal of Clinical and Laboratory Investigation, 12/19/09
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Can Prostate Specific Antigen Velocity Thresholds Decrease Insignificant Prostate Cancer Detection
The Journal of Urology, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


